X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles, administered via intratumoral injection and activated by radiotherapy. It is being evaluated for the treatment of recurrent non-small cell lung cancer.
Lead Product(s): Hafnium Oxide
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
Nanobiotx received the initial milestone payment, marking a significant step in the advancement of the pivotal Phase 3 study assessing the potential first-in-class radio enhancer NBTXR3 (cetuximab) for elderly patients diagnosed with head and neck cancer.
Lead Product(s): Hafnium Oxide
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: $2,730.0 million Upfront Cash: $60.0 million
Deal Type: Licensing Agreement January 29, 2024
Details:
The company intends to use the proceeds for the supply of NBTXR3, a novel radioenhancer composed of functionalized hafnium oxide crystalline nanoparticles, to advance the Company’s Phase 3 in the US and the EU for the treatment of locally advanced head and neck cancers.
Lead Product(s): Hafnium Oxide,Cetuximab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $34.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 07, 2023
Details:
The company intends to use the proceeds for the supply of NBTXR3, a novel radioenhancer composed of functionalized hafnium oxide crystalline nanoparticles, to advance the Company’s Phase 3 in the US and the EU for the treatment of locally advanced head and neck cancers.
Lead Product(s): Hafnium Oxide,Cetuximab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 02, 2023
Details:
NBTXR3 (hafnium oxide) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy.
Lead Product(s): Hafnium Oxide
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2023
Details:
Under the agreement, Nanobiotix will grant Janssen a worldwide license for the development and commercialization of an investigational, potential first-in-class radioenhancer NBTXR3 (hafnium oxide), currently being evaluated in several studies across solid tumor indications.
Lead Product(s): Hafnium Oxide,Cetuximab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: $3,610.0 million Upfront Cash: $60.0 million
Deal Type: Licensing Agreement July 10, 2023
Details:
NBTXR3 (hafnium oxide nanoparticles) is a novel, potentially first-in-class oncology product that is administered via one-time intratumoral injection and activated by radiotherapy.
Lead Product(s): Hafnium Oxide,Cetuximab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2022
Details:
NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy.
Lead Product(s): Hafnium Oxide
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy.
Lead Product(s): Hafnium Oxide,Pembrolizumab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
NBTXR3 (hafnium oxide) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and activated by radiotherapy.
Lead Product(s): Hafnium Oxide,Pembrolizumab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
